Shopping Cart

Your shopping cart is currently empty

Cinepazide maleate

Name: Cinepazide maleate
Brand: TargetMol
SKU: T0368
Price: 29 USD
Availability: InStock
Rating: 5 (10 reviews)

🥰Excellent

Catalog No. T0368Cas No. 26328-04-1

Alias Vasodistal, MD-67350, Brendil

Cinepazide maleate (MD-67350), a maleate salt form of cinepazide, is a vasodilator.

Cinepazide maleate

🥰Excellent

Purity: 99.97%

Catalog No. T0368Alias Vasodistal, MD-67350, BrendilCas No. 26328-04-1

Cinepazide maleate (MD-67350), a maleate salt form of cinepazide, is a vasodilator.

Pack Size	Price	USA Warehouse	Global Warehouse	Quantity
100 mg	$29	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$29	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.97%

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	Cinepazide maleate (MD-67350), a maleate salt form of cinepazide, is a vasodilator.
In vitro	Cinepazide exhibits strong chronotropic and inotropic effects. Intravenous administration of Cinepazide (1 mg/kg - 3 mg/kg) leads to an 8% increase in heart rate while reducing blood pressure by 4%. Cinepazide selectively enhances the functional activity of 5-HT neurons in the brain, although hypoxia inhibits its activity. Doses of Cinepazide (3 mg/kg - 30 mg/kg) administered intravenously transiently increase renal and femoral arterial blood flow, spinal and carotid blood flow, and cardiac output in anesthetized dogs while decreasing total peripheral resistance, exhibiting a concentration-dependent relationship with these effects. At 30 mg/kg, Cinepazide enhances the dilatory neural response of dog spinal blood vessels to intrathecal adenosine and adenylic acid. Cinepazide (1 mg - 10 mg) amplifies blood flow within spinal vessels in a dose-dependent manner, partially inhibited by pretreatment with intravenous aminophylline and unaffected by autonomic antagonists. Cinepazide is well absorbed, with over 60% excreted within 24 hours. Over five days, the excretion of Cinepazide through feces and urine is 58.3% and 36.7% in rats, 68.6% and 33.4% in dogs, and 38.1% and 61.3% in humans, respectively.
Synonyms	Vasodistal, MD-67350, Brendil

Chemical Properties

Molecular Weight	533.57
Formula	C₂₂H₃₁N₃O₅·C₄H₄O₄
Cas No.	26328-04-1
Smiles	OC(=O)\C=C/C(O)=O.COc1cc(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC
Relative Density.	1.256

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

Ethanol: < 1 mg/mL (insoluble or slightly soluble)

H2O: 98 mg/mL (183.67 mM), Sonication is recommended.

DMSO: 99 mg/mL (185.54 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.18 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

H2O/DMSO

	1mg	5mg	10mg	50mg
1 mM	1.8742 mL	9.3708 mL	18.7417 mL	93.7084 mL
5 mM	0.3748 mL	1.8742 mL	3.7483 mL	18.7417 mL
10 mM	0.1874 mL	0.9371 mL	1.8742 mL	9.3708 mL
20 mM	0.0937 mL	0.4685 mL	0.9371 mL	4.6854 mL
50 mM	0.0375 mL	0.1874 mL	0.3748 mL	1.8742 mL
100 mM	0.0187 mL	0.0937 mL	0.1874 mL	0.9371 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc